Results 181 to 190 of about 286,254 (239)

Emerging insights into amino acid metabolism in the heart: implications for cardiovascular diseases and therapeutic targeting

open access: yesBritish Journal of Pharmacology, EarlyView.
As a metabolically versatile organ, the heart is capable of generating energy from a wide range of substrates. Although fatty acid and glucose metabolism in the heart have been extensively studied, the contribution of amino acid metabolism to cardiac physiology and disease is gaining increasing attention.
Tayyiba Azam   +6 more
wiley   +1 more source

Complementary Yield of Gene Panel Testing and ACMG SF v3.3 Screening for Cardiovascular Disease in a Korean Cohort

open access: yesClinical Genetics, EarlyView.
Phenotype‐directed gene panel testing and opportunistic ACMG SF v3.3 screening identified distinct, complementary cardiovascular genetic risks in a Korean cohort. Panel testing achieved a 20.0% yield enriched for arrhythmia/cardiomyopathy genes, whereas opportunistic exome screening revealed a 5.6% yield dominated by TTN‐related cardiomyopathy and ...
Jihye You   +3 more
wiley   +1 more source

Inborn errors of immunity in children with neuroinflammation

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Abstract Inborn errors of immunity (IEIs), an expanding group of monogenic disorders with diverse clinical manifestations, are increasingly recognized to include neuroinflammatory disease. Examples of diseases included under this umbrella are Aicardi–Goutières syndrome, deficiency of adenosine deaminase 2, familial haemophagocytic lymphohistiocytosis ...
Eppie M Yiu   +5 more
wiley   +1 more source

Cardiovascular Outcomes in Semaglutide Versus Tirzepatide Users With Obesity and Atherosclerotic Disease: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for cardiovascular risk reduction in individuals with overweight or obesity and cardiovascular disease. Whether tirzepatide, a dual GLP‐1 and glucose‐dependent insulinotropic polypeptide receptor agonist, has similar cardiovascular benefits remains unknown.
Gwen Aubrac   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy